Navidea Biopharmaceuticals, Inc. (NAVB)
| Market Cap | 67.16M |
| Revenue (ttm) | 815,061 |
| Net Income (ttm) | -11.15M |
| Shares Out | 25.84M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $2.38 |
| Previous Close | $2.45 |
| Change ($) | -0.07 |
| Change (%) | -2.86% |
| Day's Open | 2.44 |
| Day's Range | 2.33 - 2.50 |
| Day's Volume | 310,000 |
| 52-Week Range | 0.63 - 5.36 |
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...
Navidea (NAVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...
Navidea Biopharmaceuticals: Too Many Risks Involved
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and...
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2020 Results - Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2020 Results - Earnings Call Transcript
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and...
Investors need to pay close attention to Navidea Biopharmaceuticals (NAVB) stock based on the movements in the options market lately.
Retail sales surging 18% in May fared well with the markets this morning, but with growing concerns over a Coronavirus resurgence, it's clear that volatility is just around the corner. We've u...
DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodia...
Live Video Moderated Discussion with CEO, Jed Latkin, to be Held on Tuesday, June 16th, at 2:00 PM ET, Immediately Followed by an Interactive Q&A Session
Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several ...
DUBLIN, Ohio, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development ...
Navidea Biopharmaceuticals Inc. (NYSE: NAVB) shares more than doubled to close out the week after the company provided an update from its midstage study in patients with active rheumatoid arth...
Shares of Navidea Biopharmaceuticals Inc. NAVB, -1.55% more than doubled in very active premarket trading Friday, after the company provided upbeat data on an ongoing phase 2 trial of its trea...
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2020 Results - Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2020 Results - Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2019 Results - Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2019 Results - Earnings Call Transcript
Navidea Biopharmaceuticals' (NAVB) CEO Jed Latkin on Q3 2019 Results - Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2019 Results - Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2019 Results - Earnings Call Transcript
For real-time updates on NAVB, beat the news and login or try Benzinga Pro. Biotechnology company that specializes in precision medicine, Navidea Biopharmaceuticals Inc (NYSE: NAVB) today had ...
Navidea Biopharmaceuticals (NAVB) CEO Jed Latkin on Q1 2019 Results - Earnings Call Transcript
About NAVB
Navidea Biopharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), ima... [Read more...]
| Industry Biotechnology | IPO Date Nov 10, 1992 |
| CEO Jed Latkin | Employees 13 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol NAVB |
Financial Performance
In 2019, NAVB's revenue was $657,826, a decrease of -43.74% compared to the previous year's $1.17 million. Losses were -$10.95 million, -32.06% less than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for NAVB stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 215.13% from the latest price.